Hostname: page-component-848d4c4894-75dct Total loading time: 0 Render date: 2024-06-09T08:28:47.805Z Has data issue: false hasContentIssue false
  • English
  • Français

Outcome Evaluation of Gabapentin as Add-on Therapy for Partial Seizures

Published online by Cambridge University Press:  18 September 2015

Joseph Bruni  and
on behalf of the "NEON" Study Investigators Group
Rights & Permissions [Opens in a new window]

Abstract:

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Objective:

The safety, tolerability, efficacy, and impact on quality of life of gabapentin (Neurontin®) as adjunctive therapy to carbamazepine (CBZ) and/or phenytoin (PHT) was assessed in epileptic patients with partial seizures.

Methods:

NEON (Neurontin Evaluation of Outcomes in Neurological Practice) was an open-label, prospective, multicentre study conducted in patients on a stable dose of CBZ and/or PHT and experiencing an average of up to 4 complex partial seizures with or without secondary generalization per month, with no seizure-free months. The treatment lasted 20 weeks. Gabapentin was started at 400 mg/day and was individually titrated to effective tolerable dose up to 2400 mg/day. Quality of life was evaluated using the QOLIE-10 questionnaire.

Results:

A total of 141 patients were enrolled at 36 sites; 114 patients were evaluable for efficacy analyses. The mean maintenance dose of gabapentin was 1600 mg/day (range = 300-3200). A decrease of 50% or more in frequency of complex partial + secondarily generalized seizures was observed in 81 (71 %) patients (p = 0.0001). Fifty two (46%) patients were seizure-free during the last 8 weeks of treatment. A significant improvement (p < 0.05) was observed in 5 of the 10 questions of the QOLIE-10, as well as in the composite QOL score (p = 0.0002). The most frequent adverse events included somnolence (16%), dizziness (9%), and asthenia (6%). Twenty-five (18%) patients prematurely discontinued the study, 16 (11%) of them due to adverse events.

Conclusion:

This study indicates that treatment with gabapentin as adjunctive therapy to standard antiepileptic drugs in this group of patients not only provides significant improvement in seizure control, but also has a positive impact on quality of life. The clinical benefits in efficacy, safety and tolerability demonstrated at 20 weeks are sustained, and no tolerance develops with gabapentin in longer term use.

Type
Original Articles
Information
Canadian Journal of Neurological Sciences , Volume 25 , Issue 2 , February 1998 , pp. 134 - 140
Copyright
Copyright © Canadian Neurological Sciences Federation 1998

References

REFERENCES

1.Mattson, RH. Efficacy and adverse effects of established and new antiepileptic drugs. Epilepsia 1995; 36 (Suppl. 2): S13-S26.CrossRefGoogle ScholarPubMed
2.á Rogvi-Hansen, B, Gram, L. Adverse effects of established and new antiepileptic drugs: an attempted comparison. Pharmacol Ther 1995; 68(3): 425–434.CrossRefGoogle Scholar
3.Dichter, MA, Brodie, MJ. New antiepileptic drugs. N Engl J Med 1996; 334(24): 1583–1590.CrossRefGoogle ScholarPubMed
4.Leach, JP, Brodie, MJ. New antiepileptic drugs – an explosion of activity. Seizure 1995; 4: 5–17.CrossRefGoogle ScholarPubMed
5.Andrews, CO, Fisher, JH. Gabapentin: a new agent for the management of epilepsy. Ann Pharmacother 1995; 28: 1188–1196.CrossRefGoogle Scholar
6.Taylor, CP. Emerging perspectives on the mechanism of action of gabapentin. Neurology 1994; 44 (Suppl. 5): S10-S16.Google ScholarPubMed
7.Bruni, J. Titration of gabapentin dose for optimal control of epileptic seizures. Adv Therapy 1996; 13(6): 324–334.Google Scholar
8.Bruni, J. Gabapentin. Can J Neurol Sci 1996; 23 (Suppl. 2): S10-S12.CrossRefGoogle ScholarPubMed
9.Proposal for revised Classification of epilepsies and epileptic syndromes. Commission on Classification and Terminology of the International League against Epilepsy. Epilepsia 1989; 30(4): 389–399.CrossRefGoogle Scholar
10.Devinsky, O, Cramer, JA and the QOLIE Development Group. Professional Postgraduate Services, a division of Physicians World Communications Group, Secaucus, NJ, USA.Google Scholar
11.Wilder, BJ. The treatment of epilepsy: an overview of clinical practices. Neurology 1995; 45 (Suppl. 2): S7-S11.Google ScholarPubMed
12.Ramsay, RE. Gabapentin: Toxicity. In: Levy, RH, Mattson, RH, Meldrum, BS, eds. Antiepileptic Drugs, 4th Ed. New York: Raven Press, 1995; 857–860.Google Scholar
13.Willmore, LJ. The effect of age on pharmacokinetics of AED’s. Epilepsia 1995; 36 (Suppl. 5): S14-S21.CrossRefGoogle Scholar
14.McLean, MJ. Clinical pharmacokinetics of gabapentin. Neurology 1994; 44 (Suppl. 5): S17-S22.Google ScholarPubMed
15.Perucca, E. Pharmacokinetic profile of topiramate in comparison with other new AED’s. Epilepsia 1996; 37 (Suppl. 2): S8-S13.CrossRefGoogle Scholar
16.Hughes, D, Cockerell, OC. A cost minimization study comparing vigabatrin, lamotrigine and gabapentin for the treatment of intractable partial epilepsy. Seizure 1996; 5: 89–95.CrossRefGoogle ScholarPubMed
17.Bruni, J. Neurontin® as add-on therapy in patients with partial seizures – long term study Proc. World Congress of Neurology [abstract] (in press).Google Scholar
18.Bruni, J. Efficacy of gabapentin (Neurontin®) as first add-on therapy in the treatment of partial seizures – long term follow-up [abstract] Epilepsia 1997; 38 (Suppl. 8): S94.Google Scholar